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SUMMARY 
Type 1 diabetes is an autoimmune disease initiated by the invasion of pancreatic islets by immune cells 
that selectively kill the β-cells. We found that rodent and human T lymphocytes release exosomes 
containing the microRNAs miR-142-3p, miR-142-5p and miR-155 which can be transferred in active 
form to β-cells favoring apoptosis. Inactivation of these miRNAs in recipient β-cells prevents 
exosome-mediated apoptosis and protects NOD mice from diabetes development. Islets from protected 
NOD mice display higher insulin levels, lower insulitis scores and reduced inflammation. Looking at 
the mechanisms underlying exosome action, we found that T lymphocyte exosomes trigger apoptosis 
and the expression of genes involved in chemokine signaling, including Ccl2, Ccl7 and Cxcl10, 
exclusively in β-cells. The induction of these genes may promote the recruitment of immune cells and 
exacerbate β-cell death during the autoimmune attack. Our data point to the exosomal-miRNA transfer 
as a communication mode between immune and insulin-secreting cells.  
 
Keywords: Exosomes, microRNAs, pancreatic β-cells, T lymphocytes, type 1 diabetes, cell-cell 
communication.  
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INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disorder characterized by infiltration of the islets of 
Langerhans by immune cells and by selective elimination of the insulin-secreting β-cells (Eizirik et 
al., 2009). The infiltration of immune cells has been observed in non-obese diabetic (NOD) mice, a 
well-known model of T1D (Anderson and Bluestone, 2005; Atkinson and Leiter, 1999), but also in the 
islets of human diabetic donors (Atkinson et al., 2014; Krogvold et al., 2016; Lundberg et al., 2017). 
Patients suffering from T1D require lifelong insulin administration to regulate whole body glucose 
metabolism and homeostasis. Understanding the dialogue between pancreatic β-cells and the 
infiltrating immune cells is crucial to promote the design of novel strategies to prevent the development 
of this disease and/or to find a cure.  
Part of the detrimental effects of the immune cells on β-cell survival is known to be exerted 
through the release of pro-inflammatory cytokines (Eizirik et al., 2009). However,  lymphocytes were 
recently found to release another class of immune mediators: the exosomes (Thery et al., 2009). 
Exosomes are small extracellular vesicles of 50-150 nm of diameter that originate from the late 
endosomal pathway and are secreted in the extracellular space upon fusion of multivesicular bodies 
with the plasma membrane (Thery et al., 2009). Exosomes are released by numerous cell types, 
including lymphocytes and pancreatic islets (Guay and Regazzi, 2015; Robbins et al., 2016), and are 
present in the blood and other body fluids (Weber et al., 2010). These extracellular vesicles transport 
proteins, mRNAs and non-coding RNAs that can be transferred in active form to recipient cells, 
suggesting an important role in cell-to-cell communication (Kosaka et al., 2010; Thomou et al., 2017; 
Valadi et al., 2007; Zhang et al., 2010). Until recently, most of the studies on exosomes were performed 
in vitro or in ex vivo cell models, but in vivo studies are now emerging. For example, the use in mice 
of the Cre-loxP system or of a human-specific miRNA elegantly demonstrated the transfer of the 
exosome cargo between distally located cells (Ridder et al., 2014; Thomou et al., 2017; Zomer et al., 
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2015). Of interest, the transfer of nucleic acids by exosomes was found to be promoted by 
inflammatory conditions (Ridder et al., 2014).  
 MicroRNAs (miRNAs) constitute one of the main cargoes transported by exosomes. These 
small non-coding RNAs are key post-transcriptional modulators of gene expression and can be 
transferred in active form via exosomes to acceptor cells (Kosaka et al., 2010; Montecalvo et al., 2012; 
Thomou et al., 2017; Valadi et al., 2007; Zhang et al., 2015). MiRNAs play an important role in the 
control of β-cell activities. Indeed, they are involved in the differentiation and functional maturation 
of β-cells and regulate insulin secretion and cell survival (Dumortier et al., 2013; Eliasson and 
Esguerra, 2014; Guay et al., 2011; Jacovetti et al., 2015; Lynn et al., 2007). Deregulation of miRNA 
expression has been associated with the development of T1D and T2D and with age-associated decline 
in β-cell proliferation (Filios and Shalev, 2015; Guay and Regazzi, 2016; Nesca et al., 2013; Tugay et 
al., 2016). Moreover, some miRNAs were found to induce β-cell dysfunction and death under 
inflammatory conditions in both rodent and human islets (Grieco et al., 2017; Roggli et al., 2012). 
In the present study, we investigated the involvement of miRNAs in the initial phases of T1D 
development in NOD mice. We found that islet insulitis is associated with an exosome-mediated 
transfer of a particular group of miRNAs, namely miR-142-3p, miR-142-5p and miR-155, from 
lymphocytes to β-cells, resulting in the selective death of the insulin-secreting cells. In vitro, 
inactivation of these miRNAs inside the β-cells protected them against apoptosis induced by T 
lymphocyte exosomes and, in vivo, prevented T1D development in NOD mice. Taken together, our 
results suggest that the transfer of miRNAs mediated by exosomes released by lymphocytes 
contributes to the destruction of the β-cells and could be part of the mechanisms leading to T1D 
development. 
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RESULTS  
Increased abundance of miR-142-3p, miR-142-5p and miR-155 in β-cells of pre-diabetic NOD mice. 
In a previous study, we performed a global miRNA expression profiling of pancreatic islets of 4 and 
8 weeks-old female NOD mice (which correspond to control and pre-diabetic state, respectively) to 
understand the role of miRNAs in β-cell death associated with T1D development (Roggli et al., 2012). 
At 8 weeks of age, NOD mice are still normoglycemic but T lymphocytes are starting to infiltrate the 
islets (Roggli et al., 2012). The miRNAs displaying the most important deregulation in the islets of 8 
weeks old animals were miR-142-3p/-5p, miR-150 and miR-155, which are known to control the 
activity of immune cells (Dudda et al., 2013; Kroesen et al., 2015; Wu et al., 2007) but are normally 
expressed at very low levels in insulin-secreting cells. Indeed, we found that these miRNAs are much 
more abundant in lymphocytes compared to islet cells (Figure S1A). The expression of these miRNAs 
is modified to a much lesser extent in the islets of age-matched diabetes-free NOD-SCID mice (Figure 
1A), indicating that the changes observed in pre-diabetic mice are most likely linked to the 
development of the disease. The increase in the levels of miR-142-3p/-5p and miR-155 were detected 
also in FACS-sorted β-cells of pre-diabetic NOD mice (Figure 1B), confirming that the rise of these 
miRNAs occurs in insulin-secreting cells. In agreement with previous findings in rat islets (Bravo-
Egana et al., 2012), the expression of these miRNAs was not affected by incubation of control 
C57Bl/6N mouse islets with the pro-inflammatory cytokines IFNγ, TNFα and IL-1β (Figure 1C). 
Therefore, the increase of miR-142-3p/-5p and miR-155 in β-cells in 8 weeks old NOD mice is unlikely 
to be caused by cytokines secreted by immune cells infiltrating the islets.  
 
T lymphocytes release exosomes containing miR-142-3p, miR-142-5p and miR-155.  
Since immune cells release large amounts of exosomes, we hypothesized that the rise of miR-142-3p/-
5p, and miR-155 in islet cells of pre-diabetic animals may result from an exosome-mediated transfer 
favored by the proximity of T lymphocytes and β-cells during the initial phases of the disease. To 
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explore this hypothesis, we isolated by ultracentrifugation the vesicles released by human Jurkat T 
cells (exoT) and by CD4+/CD25- T lymphocytes of NOD mice (exoNOD). Analysis of these 
preparations by electron microscopy (Figure 2A-B) and Nanosight technology (Figure 2D-E) revealed 
the presence of round-shaped small extracellular vesicles surrounded by a lipid bilayer membrane with 
a diameter of 50-200 nm. These small extracellular vesicles carried the characteristic exosomal 
markers CD81, Alix and Tsg101 (Thery et al., 2009) (Figure 2C). We next investigated if these small 
extracellular vesicles can be efficiently internalized by insulin-secreting cells. After an overnight 
incubation, DiD-labelled exoT were found to be taken up by most cells of the β-cell line MIN6B1 
(Figure 2F).  
We next examined the miRNA content of T cell exosomes. All three miRNAs, miR-142-3p/-
5p and miR-155, were found to be present in the extracellular vesicles released by T lymphocytes 
(Figure S1B-C). To ensure that these miRNAs are confined inside exosomes, the samples were treated 
with RNase. In contrast to a synthetic oligonucleotide (miR-29a mimic) spiked into the samples, the 
level of the endogenous miRNAs was not affected by the RNase treatment and were degraded only 
when the exosome membrane integrity was altered with the detergent Triton X-100 (Figure 2G).  
 
Exosomal miRNAs from T lymphocytes are transferred to β-cells.  
To assess whether the miRNAs present in the exosomes of T lymphocytes can be transferred to β-
cells, dispersed mouse islet cells were incubated with exoNOD for 72h (Figure 3A). This treatment 
led to a significant increase in the abundance of miR-142-3p/-5p and miR-155 in islet cells (Figure 
3B). Similar results were obtained when MIN6B1 or rodent islet cells were exposed to exoT (Figure 
3C and Figure S2B). The sequence of miR-142-3p and miR-142-5p is identical in humans and rodents 
and, therefore, it is not possible to distinguish the miRNAs delivered via the exosomes from those 
endogenously produced in mouse or rat β-cells. In contrast, human miR-155 (hsa-miR-155) differs by 
one nucleotide from its rodent counterparts (Figure S2A) and can be readily distinguished by qPCR 
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using species-specific primers (Table S1). This strategy enabled us to show that the rise of miR-155 
observed in the receiving rodent islet cells is entirely due to an exosome-mediated transfer of hsa-miR-
155 from the human Jurkat T cell line and not from an increase synthesis of endogenous mmu-miR-
155 (Figure 3C-D and Figure S2C). This finding was further confirmed using exosomes purified from 
CD4+/CD25- T cells of miR-155 knock-out mice (Figure S2D-E). Indeed, while the other miRNAs 
were still increased in recipient MIN6B1 cells, the level of miR-155 remained unchanged upon 
incubation with exosomes isolated from miR-155 knock-out mice (Figure S2F-H). To demonstrate 
that hsa-miR-155 is transferred in active form inside the β-cells, the receiving cells were transfected 
with a luciferase sensor. As expected the incubation of MIN6B1 cells with exoT for 48h or 72h led to 
a decrease in the luciferase activity of the hsa-miR-155 sensor (Figure 3E), confirming that the miRNA 
is transferred in active form in the receiving cells. Taken together, these results provide evidence for 
an exosome-mediated transfer of miRNAs from immune cells to β-cells analogous to that observed in 
other biological processes (Ridder et al., 2014; Thomou et al., 2017; Zhang et al., 2015). 
 
T lymphocyte exosomes promote β-cell apoptosis and induce the upregulation of genes involved in 
cytokine and chemokine signaling.  
We next investigated the impact of T lymphocyte exosomes on β-cell function and survival. Incubation 
of β-cells in the presence of exoT did not affect insulin secretion or content (Figure S3A-D) but led to 
a significant increase in cell apoptosis, which was prevented by the pan-caspase inhibitor zVAD 
(Figure 3F-G and Figure S3E-F). The cytotoxic action of T cell exosomes was reproduced in dispersed 
mouse islet cells incubated with exosomes from T cells of NOD mice (Figure 3H). The apoptotic effect 
of exoT cannot be attributed to the presence of residual traces of cytokines released by lymphocytes. 
In fact, incubation of β-cells in the medium surrounding the purified exosomes did not modify the level 
of the miRNAs and did not affect the survival of the cells (Figure S3G-H). To determine if this process 
occurs also in human, human islet cells were incubated with exosomes (exo-hT) of CD4+ T cells 
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isolated from human blood donors. Similar to the findings obtained in rodents, exposure of human islet 
cells to exo-hT resulted in the transfer of miR-142-3p, miR-142-5p and miR-155 (Figure 3I) and in an 
increase in cell death measured by Hoechst or by TUNEL staining (Figure 3J-K).  
 Interestingly, the cytotoxic effect of the exosomes was restricted to β-cells. Indeed, the increase 
in apoptosis was reproduced in FACS-sorted rat β-cells (98±2% purity) but not in an α-cell-enriched 
fraction (91±4% α-cells) (Figure 4A-B). To assess whether this cell-specific effect is due to a selective 
uptake of the exosomes, we took advantage of the auto-fluorescence properties of the rodent β-cells 
(Kohler et al., 2012). Image Stream Flow Cytometry, revealed that DiD-labelled exoT can be equally 
detected in auto-fluorescent β-cells and in non-fluorescent islet-cells (Figure 4C). Consistent with 
these findings, upon incubation with exoNOD miR-142-3p, miR-142-5p and miR-155 were transferred 
to both FACS-sorted α- and β-cells (Figure 4D-E, respectively).  
 To elucidate the mechanisms through which T-cell exosomes exert their effect on β-cells, we 
analyzed by microarray the changes in the mRNA profile elicited in mouse islet cells by exoNOD. 
Upon exposure to exoNOD, we detected about 90 up-regulated and 20 down-regulated genes (nominal 
p-value < 0.05 and fold change > 2) (Table S2). Pathway analysis revealed a significant enrichment 
for genes involved in cytokine and chemokine signaling, including Ccl2, Ccl7 and IFNg (Figure S4A). 
Several of these changes were confirmed by qPCR (Figure 5A-B). Using this technique, we also 
obtained evidence for an increase in Cxcl10 (p=0.05), a chemokine known to be involved in type 1 
diabetes development (Frigerio et al., 2002; Roep et al., 2010) (Figure 5A). The array data revealed 
also a strong increase in the level of the Eosinophil-associated ribonuclease family members, Ear1, 
Ear2 and Ear12 (Table S2). The role of these RNases in β-cells has so far not been explored but, in 
other cell-types, Ear proteins have cytotoxic and chemoattractant effects (Gupta et al., 2013; 
Rosenberg, 2015). Interestingly, overexpression of miR-142-3p/-5p and miR-155 in mouse islet cells 
led to an increase in the level of Ccl2, Ccl7 and Cxcl10 similar to that observed upon incubation with 
exoNOD (Figure 5C), indicating that at least part of the effect of the exosomes is mediated by the 
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transfer of these miRNAs. Exposure of human islets to the exosomes released by activated human 
CD4+ T cells (exo-hT) led to a similar increase in CCL2, CCL7 and CXCL10 (Figure 5D), indicating 
that this phenomenon is not restricted to rodents. 
To better understand the cell-specific apoptotic effect of exosomes, we incubated FACS-sorted 
α- and β-cells with exoNOD for 72h. We found that miRNAs are transferred to both cell types (see 
Figure 4D-E), but the rise of Ccl2, and Cxcl10 was only observed in β-cells (Figure 5E). A similar 
trend was observed for Ccl7. These results suggest that the selective effect of the exosomes is likely 
to be caused by the activation of cell-death signaling pathways operating predominantly in β-cells.  
Several of the differentially expressed genes are elicited in response to the activation of NFκB, 
a signaling pathway known to trigger β-cells apoptosis (Melloul, 2008). Consistent with this 
observation, exposure of MIN6B1 cells to ExoT was associated with a nuclear translocation of NFκB 
(Figure 5F + Figure S4). The fraction of cells in which NFκB localized in the nucleus after ExoT 
treatment was very similar to that observed upon exposure to pro-inflammatory cytokines (Figure 5F). 
Interestingly, the translocation of the transcription factor could be reproduced by directly 
overexpressing miR-142-3p, miR-142-5p or miR-155 (Figure 5F), confirming a causal link with the 
transfer of these miRNAs. 
 
Inactivation of miR-142-3p, miR-142-5p and miR-155 prevents exosome-induced cell death.  
To determine whether the transferred miRNAs contribute to the deleterious effect of T-cell exosomes 
on β-cell activities, we directly increased their level using miRNA mimics (Figure S5A,C). While none 
of the tested miRNAs affected insulin secretion or content (Figure 6A +Figure S5B), overexpression 
of miR-142-3p, miR-142-5p or miR-155 increased apoptosis both in MIN6B1 (Figure S5D) and rat 
islet cells (Figure 6B). If the transfer of specific miRNAs from T cells to β-cells contributes to 
apoptosis induced by exosomes, then inactivation of these miRNAs in receiving cells should prevent 
cell death. We first verified this hypothesis in vitro using anti-miRs that specifically block the action 
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of the transferred miRNAs. Anti-miRs will not avoid the transfer of the miRNAs but will sequester 
them upon delivery inside the recipient β-cells, blocking the interaction with their targets. Transfection 
of islet cells with anti-miR-142-3p, anti-miR-142-5p or anti-hsa-miR-155 attenuated the rise of these 
non-coding RNAs (Figure S6A-C) and prevented apoptosis induced by exoT (Figure 6C). This effect 
was specific to exosome-induced apoptosis since these anti-miRs failed to protect β-cells exposed to 
pro-inflammatory cytokines (Figure S6E-G). While decreasing the level of endogenous miR-155, 
transfection of rat islet cells with an anti-miR against murine miR-155 did not prevent cell death 
(Figure 6C and Figure S6D). Taken together, these results suggest that miR-142-3p, miR-142-5p and 
miR-155 transferred by exosomes from T lymphocytes to β-cells induce recipient cell death. 
 
Injection of a miRNA sponge in 4 weeks old NOD mice prevents T1D development.  
Our findings suggest that a transfer of a subset of miRNAs from immune cells to β-cells taking place 
during the initial phases of T1D could potentially contribute to the development of the disease. To 
assess the pathophysiological relevance of this exosome-mediated cell-to-cell signaling in vivo, we 
engineered an Adeno Associated Virus (AAV) producing a GFP transcript containing multiple binding 
sites for miR-142-3p/-5p, miR-150 and miR-155. This “miRNA sponge” is driven by the insulin 
promoter and specifically sequesters these miRNAs once delivered inside the β-cells (Figure 7A) 
(Ebert et al., 2007). As at the beginning of our study it was not clear whether miR-150 would be 
involved in diabetes development, we decided to include in the construct also the binding site of this 
miRNA. The miRNA sponge or a control AAV lacking the miRNA binding sites were intraperitoneally 
injected in 4 weeks-old female NOD mice. As expected, GFP mRNA and protein expression was 
detected in the islet of 8 weeks-old mice injected with the sponge or the control AAV (Figure S7A-B). 
Importantly, GFP was not detected in the exocrine pancreas and in immune cells invading the islets, 
confirming the specificity of the insulin promotor (Figure S7C). At 8 weeks of age, both control and 
sponge-treated NOD mice displayed similar body weights, plasma glucose levels and glucose tolerance 
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and showed low levels of lymphocyte infiltration (Figure S7D-F + S8A-B). However, while at 32 
weeks of age 80% of the control mice became diabetic, only 40% of the animals receiving the miRNA 
sponge developed the disease (Figure 7B). Histological analysis of the pancreases at the time of 
sacrifice revealed that these disease-free mice (Sp-prot) retain a higher insulin volume compared to 
the animals developing diabetes (Figure 7C). Moreover, their islets more often displayed low insulitis 
scores (Figure 7D). This was not associated with an increase in FoxP3-positive Treg lymphocytes 
suggesting a decrease in inflammation rather than changes in the cell populations of the immune 
infiltrate (Figure S8C). Consistent with this hypothesis, we found reduced levels of CXCL10 in islet 
cells (Figure 7E). In line with our in vitro observations, CXCL10 was more frequently found in insulin-
positive cells compared to glucagon-positive cells and the expression of this chemokine in β-cells was 
significantly reduced in sponge-protected mice (Figure 7E). CXCL10 levels were already lower in 
sponge-treated 8 weeks-old mice compared to control animals suggesting a diminished 
chemoattractant ability of the β-cells expressing the miRNA sponge (Figure 7F).  
Taken together, these in vivo data support the relevance of the exosome-mediated transfer of genetic 
material in the autoimmune reaction and indicate that the inactivation of miR-142-3p/-5p, miR-150 
and miR-155 in β-cells is able to protect NOD mice against T1D development.  
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DISCUSSION 
 The autoimmune attack of β-cells is a hallmark of T1D, but the events culminating in the 
specific loss of the insulin-secreting cells remain poorly understood. In the present study, we provide 
evidence for the involvement of an exosome-mediated transfer of miRNAs from T lymphocytes to β-
cells in the initial phases of T1D development. Exosomes have been shown to participate to the 
etiology of other autoimmune disorders (Robbins et al., 2016; Turpin et al., 2016). Indeed, these small 
extracellular vesicles can activate specific signal transduction pathways, participate in the formation 
of immune complexes and synapses, and contribute to the maintenance of the inflammatory status. We 
observed that exposure of β-cells to exosomes released from T lymphocytes does not alter their 
secretory capacity but increase their apoptotic rate. An important feature of the autoimmune attack of 
pancreatic islets is the selective killing of the β-cells. Interestingly, the exosomes released by T cells 
reproduce this β-cell specific event and have no deleterious impact on α-cells. This cell selectivity 
cannot be explained by a specific targeting of the exosomes to β-cells, since these small extracellular 
vesicles are internalized by other islet cell types. β-cell-specific apoptosis is most likely the result of 
the activation by exosomes of cell death pathways operating only in insulin-secreting cells. Human 
and rodent α-cells have been reported to be resistant to metabolic and immune stresses that induce β-
cell death (Marroqui et al., 2015; Takeda et al., 2012; Vasu et al., 2015). In agreement with this 
hypothesis, Ccl2, Ccl7 and Cxcl10 were solely increased in β-cells and not in α-cells upon exosome 
treatment. Moreover, in NOD mice developing diabetes CXCL10 was more frequently detected in 
insulin-positive cells than in glucagon-positive cells.  
  The exosome cargo includes proteins and nucleic acids, in particular miRNAs. We previously 
identified a subset of miRNAs that are highly abundant in the islets of pre-diabetic NOD mice (Roggli 
et al., 2012). We show here that this increase cannot be explained by the exposure of β-cells to pro-
inflammatory cytokines but is rather the result of an exosome-mediated shuttling of miR-142-3p/-5p 
and miR-155 from T lymphocytes to β-cells. Our data provide strong evidence indicating that the 
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transfer of these miRNAs is instrumental to induce β-cell death. Indeed, overexpression of these 
miRNAs is sufficient to induce β-cell apoptosis and blockade of these miRNAs inside the β-cells 
prevents apoptosis induced by T-cell exosomes but not by pro-inflammatory cytokines. Individually, 
none of the predicted targets of the miRNAs is able to explain the activation of NFkB or the observed 
increase in apoptosis. This is not surprising because miRNAs are known to function by inducing 
relatively small changes in the expression of a large number of genes rather than by causing major 
changes in the level of a single transcript. Computational analysis suggests that miR-142-3p, miR-142-
5p and miR-155 share some common targets (Table S3), some of which are known to participate to 
the regulation of cytokine and/or NFκB signaling. Thus, the signaling cascades activated in response 
to a rise of these miRNAs may potentially converge. Indeed, in agreement with reports in other cell 
types (Sharma et al., 2012; Yin et al., 2017), miR-142-3p, miR-142-5p and miR-155 were all found to 
modulate NFκB activity, pointing to a common mode of action. Thus, although the overexpression of 
each individual miRNA can potentially lead to cell death, the effect of the T cell exosomes is likely to 
result from the synergistic action of the three miRNAs. In fact, blockade of any of the three transferred 
miRNAs was sufficient to prevent exosome-induced apoptosis.  
 We were able to prove the relevance of this novel exosome-mediated cell-to-cell 
communication mode for T1D development by taking advantage of an AAV construct containing 
multiple binding sites for miR-142-3p/-5p, miR-150 and miR-155. Indeed, NOD mice injected with 
this miRNA sponge showed a 50% reduction in the incidence of the disease compared to the control 
group. As expected, this protection against T1D development was accompanied with a higher islet 
insulin volume and lower insulitis scores. Whether the protective effect of the miRNA sponge is 
limited to β-cell death or prevents also the initial steps of the disease remains to be defined. Since an 
efficient transfer of miRNAs from lymphocytes to β-cells involves the close proximity of the two cells, 
this event is very unlikely to constitute the initial trigger of the disease. However, once the autoimmune 
reaction has been initiated by viral antigens, autoantigens or other inflammatory mediators and 
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immune cells are recruited to the islets, β-cell chemokine production resulting from the transfer of the 
miRNAs may contribute to maintain and further exacerbate the insulitis. This scenario is consistent 
with the reduced immune infiltration of the islets observed in mice treated with the miRNA sponge. 
To precisely define the contribution of exosome-mediated miRNA transfer to the different stages of 
the diseases, large cross-sectional studies monitoring the impact of the miRNA sponge on insulitis 
progression and β-cell loss during the natural course of diabetes will be needed.  
Interestingly, Ying and colleagues recently demonstrated the detrimental effect of miR-155 
released in exosomes from macrophages residing in adipose tissue of obese mice on systemic insulin 
sensitivity and glucose tolerance. These metabolic markers were improved in miR-155 knockout 
animals (Ying et al., 2017). Therefore, the release by immune cells of miR-155 in exosomes may 
possibly be implicated in the etiology of both T1D and T2D.  
  The precise mechanisms through which the exosomes of T lymphocytes trigger β-cell death 
remain to be fully established. In vitro, activation of NFκB signaling as well as the induction of several 
members of the Ear family that are cytotoxic in other cell types (Gupta et al., 2013; Rosenberg, 2015) 
may contribute to the increase in the apoptotic rate observed upon exposure to exosomes. In vivo, T 
lymphocyte exosomes may be part of the mechanisms favoring islet inflammation, insulitis 
progression and T1D development. Under inflammatory conditions, β-cells are known to produce 
chemokines such as CCL2 and CXCL10 that are believed to favor insulitis and diabetes development 
(Frigerio et al., 2002; Martin et al., 2008). The expression of these inflammatory mediators was also 
observed in pancreatic sections or in islet samples of human T1D donors (Eizirik et al., 2012; Roep et 
al., 2010). In our study, global expression profiling of mouse islets incubated with exosomes from 
NOD T effector cells revealed the up-regulation of several genes linked to cytokine and chemokine 
signaling, including Ccl2, Ccl7, Cxcl10 and Ifng. Interestingly, Ccl2 was found to modulate NFκB 
signaling in MIN6 cells (Cai et al., 2011) and other cell types (Viedt et al., 2002; Viedt and Orth, 
2002). At least part of these gene expression changes may be driven by the transfer of miRNAs from 
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immune cells to β-cells. Indeed, overexpression of miR-142-3p, miR-142-5p and miR-155 in β-cells 
led to an increase in Ccl2, Ccl7 and Cxcl10 expression and favored nuclear translocation of NFκB. 
CXCL10 levels are reduced in β-cells of NOD mice injected with the AAV-sponge and protected from 
diabetes development. Therefore, in vivo, the exposure to exosomes may exacerbate the release of 
cytokines and chemokines from β-cells elicited in response to inflammatory mediators produced by T 
lymphocytes, favoring insulitis progression and T1D development.  
The exosome-mediated dialogue between lymphocytes and β-cells may operate in both 
directions. Indeed, these vesicles were reported in other immune diseases to activate T lymphocytes 
either directly or indirectly via the antigen-presenting cells (Turpin et al., 2016). The release of 
exosomes from human and rodent islet cells or by insulinoma cell lines has been reported by several 
laboratories (Bashratyan et al., 2013; Cianciaruso et al., 2017; Guay et al., 2015; Sheng et al., 2011). 
Sheng and colleagues (Sheng et al., 2011) observed that injection of exosomes produced by MIN6 
cells in NOR mice favors lymphocyte islet infiltration and increases insulitis. In vitro, exosomes from 
MIN6 cells were found to trigger both innate and antigen-specific signals by inducing lymphocyte 
proliferation and by activating autoreactive T-helper 1 cells and marginal zone-like B cells (Bashratyan 
et al., 2013; Sheng et al., 2011). The precise mechanisms through which β-cell exosomes trigger the 
immune response remain to be unveiled. Exosomes released by rat and human islet cells contain three 
autoantigens linked to T1D, namely GAD65, IA-2 and proinsulin, and are taken up by dendritic cells 
causing their activation (Cianciaruso et al., 2017). The presence of these autoantigens in exosomes 
released by β-cells could explain how these proteins become the target of the immune system even if 
they are localized mainly inside the cells. Indeed, exosome-mimetic liposomes transporting GAD65 
could favor antigen presentation and T-cell activation. Finally, other components of β-cell exosomes 
were also involved in stimulation of antigen-presenting cells (Cianciaruso et al., 2017). 
In the present study, we focused on miRNAs transferred from CD4+ T effector cells to β-cells. 
However, other immune cells infiltrating the islets release exosomes with a similar miRNA content. 
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For example, miR-150 and miR-155 are released in exosomes originating from monocytes and 
macrophages, respectively, and have functional impacts on recipient cells (Ying et al., 2017; Zhang et 
al., 2010). The composition of the immune infiltrate and the origin of the exosomes may differ with 
the progression of the disease. Our data do not exclude the contribution of exosomes produced by other 
immune cells infiltrating the islets in β-cell dysfunction and loss. We believe that the transfer of 
miRNAs to β-cells during T1D development is mainly promoted by the close proximity of the activated 
immune cells that invade the islets. However, the amount and the composition of the exosome cargo 
varies depending on the activation state of the immune cells (Gutierrez-Vazquez et al., 2013; Okoye 
et al., 2014; van der Vlist et al., 2012). Indeed, the exosomes released by active T cells were reported 
to contain higher levels of miR-142-3p (Sukma Dewi et al., 2017). In vivo, it is possible that the 
presence of autoreactive T cell receptors or of other specific components at the exosome surface of 
infiltrating immune cells may facilitate the fusion with the β-cells and the delivery of the miRNAs. 
Moreover, the exosomes released by immune cells may carry additional molecules potentially 
affecting the activity of the target cells, including other RNAs, proteins and lipids. A better 
understanding of the mechanisms governing the targeting of the exosomes and of the cargo they deliver 
will not only help elucidating the mechanisms triggering T1D but may also shed new light on the 
etiology of other autoimmune diseases.  
 
Our findings have relevant implications for the design of better approaches to prevent T1D 
development. Strategies to avert the loss of β-cells will need to take into account the existence of this 
newly discovered cell-to-cell signaling mechanism. The exosome-mediated transfer of miRNAs with 
harmful effects on β-cells is probably exacerbating the deleterious impact of pro-inflammatory 
cytokines released by the invading immune cells and is likely to synergize with other well-described 
events involved in the autoimmune reaction. Thus, therapeutic interventions tackling several aspects 
of the immune attack would probably be more effective in protecting the β-cells.  
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Limitations of the study 
In this study, we showed that a viral construct blocking the activity of a group of miRNAs transferred 
from lymphocytes to β-cells reduces the incidence of T1D in NOD mice. Although these mice 
constitute a widely used model of T1D and reproduce many of the feature of the disease in humans 
(Pearson et al., 2016), additional investigations will be needed to assess the translational potential of 
our findings. In fact, human T1D is characterized by less pronounced intra-islet infiltration and several 
immunotherapies preventing the disease in NOD mice were found to be inefficient in humans (Kolb 
and von Herrath, 2017). Future experiments will also have to investigate the efficacy of the treatment 
at different stages of the disease. Indeed, in this study the miRNA sponge was injected prior to the 
initiation of the autoimmune reaction and we ignore whether the treatment would be equally efficient 
after intra-islet infiltration has occurred. This information will be essential to evaluate the therapeutic 
potential for human T1D of strategies targeting the exosome-mediated process unveiled in this study.  
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FIGURE LEGENDS 
Figure 1 - Deregulation of miRNA levels in β-cells of prediabetic NOD mice A) Abundance of the 
indicated miRNAs in A) islets of diabetes-free SCID-NOD mice (n=3 indep. exp.) or B) in FACS-
sorted β-cells of NOD mice (n=4 indep. exp.) aged of 4 and 8 weeks. C) Islets of control C57Bl/6N 
mice were incubated in the presence of pro-inflammatory cytokines (IFNγ, TNFα and IL-1β) (n=6 
indep. exp.). miRNA levels were determined by qPCR and are expressed as fold change vs 4 weeks or 
control (Ctl) condition (white bars). miR-146a was used as a positive control for cytokine treatment. * 
p < 0.05, ** p < 0.01 by Student’s t-test. See also Figure S1. 
 
Figure 2 - Characterization of the exosomes released by T lymphocytes. Exosomes were isolated from 
the culture media of Jurkat cells (exoT) or NOD T lymphocytes (exoNOD) by sequential 
centrifugation. A-B) Visualization of the extracellular vesicles (arrows) by electron microscopy (scale 
bar = 100nm). C) Analysis of the presence of the exosomal markers Alix, CD81 and Tsg101 by western 
blotting in our extracellular vesicle preparations. The supernatant surrounding the exosome pellet after 
ultra-centrifugation was used as negative control (Neg. Ctl). Analysis of the size distribution of D) 
ExoT and E) ExoNOD vesicles using the Nanosight technology. F) Image stream flow cytometry 
analysis of MIN6B1 cells incubated with DiD-labelled ExoT (4 representative pictures out of 20’171 
cells analyzed). Scale bar = 7µm. G) miRNA levels in exoT. A miR-29a mimic, used as positive control 
for RNAse digestion, was spiked in the ExoT preparation. The samples were then treated or not (NT) 
with Triton X-100 (T) and incubated with RNAses (+R). miRNA levels were measured by qPCR and 
are expressed as percentage of NT (n=3 indep. exp). 
 
Figure 3 - T cell exosomes transfer miRNAs to β-cells and induce their death. A) Schematic 
representation of the in vitro exosome transfer experiments. CD4+CD25- T lymphocytes were isolated 
from mouse spleen (or alternatively from human blood samples) and cultured for 72h in the presence 
27 
 
of CD3CD28 activation beads, IL-2 and IL-12. Exosomes were isolated from the culture media by 
ultra-centrifugation and added to recipient islet cells. Mouse islet cells (B,H) were incubated with 
exoNOD, rat islet cells (C-D,F-G) with exoT and human islet cells (I-K) with exo-hT (n=4-5 indep. 
exp.) for 48-72h. At the end of the incubation, miRNA abundance was measured by qPCR and was 
expressed as Fold changes vs Ctl (B-C, I) or as RFU if the miRNA was undetectable under control 
condition (D). E) Luciferase activity was measured in MIN6B1 cells transfected with the hsa-miR-155 
sensor and treated with exoT for 48h or 72h (arbitrary unit AU). F-H, J) Apoptosis was assessed by 
scoring the cells displaying pycnotic nuclei upon Hoechst staining without or with the pan-caspase 
inhibitor zVAD, or (K) using TUNEL assay. *,# p < 0.05, **,## p < 0.01 by Student’s t-test or by one-
way Anova, Dunnett’s post-hoc test for multiple comparison. See also Figure S2-S3 and Table S1. 
 
Figure 4 - T cell exosomes induce specifically β-cell death. FACS-sorted rat islet fractions enriched 
for (A) β- or (B) α-cells were incubated with exoT for 72h. Apoptosis was assessed by scoring the cells 
displaying pycnotic nuclei upon Hoechst staining (A: n=5, B: n=3 indep. exp.). C) Analysis by Image 
stream flow cytometry of rat islet cells incubated with DiD-exoT. Two representative images out of 
10’089 cells analyzed. FACS-sorted rat islet fractions enriched for β- (D) or α-cells (E) were incubated 
with exoNOD for 72h. miRNA levels were measured by qPCR and are expressed as Fold changes vs 
Ctl (n=3 indep. exp) * p < 0.05, ** p < 0.01  by Student’s t-test. 
 
Figure 5 - Regulation of β-cell gene expression by T cell exosomes. A-B) Confirmation by qPCR of 
gene expression changes observed by global microarray profiling of mouse islet cells incubated with 
exoNOD. C-E) Gene expression levels were measured by qPCR in C) dispersed mouse islet cells 
transfected with miR-142-3p, miR-142-5p and miR-155 mimics, D) human islet cells incubated with 
exo-hT and E) FACS-sorted rat islet fractions enriched for α- or β-cells incubated with exoNOD. The 
results are expressed as Fold changes  (A, C, D, E) or as relative fluorescent units (RFU) (B), Ifng 
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being not detected under control condition (n=4 indep. exp.).  F) Nuclear translocation of NFκB in 
MIN6B1 cells incubated with exoT or pro-inflammatory cytokines (IFNγ, TNFα and IL-1β), or 
transfected with miR-142-3p, miR-142-5p and miR-155 mimics (n=3-4 indep. exp.). * p < 0.05, ** p 
< 0.01 Student’s t-test. See also Figure S4 and Table S2. 
 
Figure 6 - Effects of miR-142-3p/-5p and miR-155 deregulation on β-cell function and survival. A-B) 
Dispersed rat islet cells were transfected with the indicated miRNA mimics. A) Insulin secretion in 
response to 2 or 20 mM glucose (2G or 20G) was measured by ELISA (n=3-6 indep. exp.). B) 
Apoptosis was assessed by Hoechst staining (n=4 indep. exp.). Cytokine mix (Cyt) was used as 
positive control. * p < 0.05, ** p < 0.01 by Student’s t-test. C) Dispersed rat islet cells were transfected 
with the indicated antimiR and incubated with exoT for 72h. At the end of the incubation period, 
apoptosis was determined by scoring the cells displaying pycnotic nuclei upon Hoechst staining (n=4 
indep. exp.). *, # p < 0.05. **, ## p < 0.01 by one-way Anova, Dunnett’s post-hoc test. See also Figure 
S5 and S6. 
 
Figure 7 - Inactivation of miR-142-3p/-5p, miR-150 and miR-155 in β-cells of NOD mice reduces the 
incidence of T1D. A) Schematic representation of the AAV producing a GFP transcript containing 
multiple binding sites for miR-142-3p/-5p, miR-150 and miR-155 (miRNA sponge) driven by the 
insulin promotor (RIP). The AAV-sponge (Sp) or a control AAV lacking the miRNA binding sites 
(Ctl) were injected intraperitoneally in NOD mice aged of 4 weeks. B) Diabetes-free animals 
displaying a glycemia below 14 mM, in the group of mice injected with the AAV-sponge and with 
AAV-ctl. Total of n=15-16 mice, 3 independent experiments, p=0,0267, by log-rank test. C) Insulin 
volume determined by immunostaining in AAV-sponge injected animals that developed diabetes (Sp-
not protected) or remained disease-free (Sp-protected) until 32 weeks of age (n=70 pancreatic sections, 
from 3 different mice per group). ** p < 0.01 by Mann-Whitney U test. D) Insulitis score measured at 
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the time of sacrifice in the pancreases of AAV-sponge injected mice that were protected (Sp-prot) or 
not (Sp-NP) from diabetes development (n=3 mice per group). E) Colocalization of CXCL10 (Red) 
with insulin- (Green, yellow arrows) or Glucagon- (Blue, red arrows) in 32 weeks old NOD mice 
injected with the AAV-sponge developing (SP-NP) or not (SP-prot.) diabetes. F) CXCL10 levels (Red) 
normalized to islet insulin volume (Green) in 8 weeks old NOD mice injected with AAV-Ctl (Ctl) or 
AAV-sponge (Sp). Nuclei were stained with Dapi (blue) (E) n=35, and (F) n=180 pancreatic sections, 
from 3 different mice per group. ** p < 0.01 by  Mann-Whitney U test or by one-way Anova, Tukey’s 
post-hoc test. See also Figure S7-S8. 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by the Lead Contact, Dr. Romano Regazzi (romano.regazzi@unil.ch). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Rodent - All animal procedures were performed in accordance with the NIH guidelines and protocols 
were approved by the Swiss Research Councils and Veterinary Offices or the Ethical Committee for 
Animal Experiments of the University of Groningen. Male Wistar rats (200-250g) and 4-8 weeks old 
female NOD/ShiLtJ mice were obtained from Charles River Laboratories (L’arbresle, France). Male 
C57Bl/6N mice (12-15 week-old) and 4 and 8 weeks-old female NOD scid mice (NOD.CB17-
Prkdcscid/Rj) were from Janvier Labs (Le Genest St-Isle, France). miR-155 knock-out mice (miR-
155-/-) were from Jackson Laboratories (Jax 007745).  
Human islets - Human islet preparation were obtained from Tetu-Bio (Lot HP-18157-01, Germany) 
or from the Centre d’Etude Européen pour le Diabète in Strasbourg (isolation protocol authorization 
for scientific research #PFS12-0013). Dissociated islet cells were cultured in CMRL medium 
(Invitrogen) supplemented with 10% fetal calf serum (Gibco), 10 mM Hepes pH 7.4, 100 μg/mL 
streptomycin and 100 IU/mL penicillin and 2 mmol/l glutamine. Detailed information about human 
islet donors are provided in Table S4 and in Key Resources Tables. 
Cell lines –Jurkat cells (J77 clone 20 from O. Acuto) (Rebeaud et al., 2008) were cultured in RPMI 
1640 medium supplemented with 10% fetal calf serum (previously depleted from serum-exosomes), 
50 μg/mL streptomycin and 50 IU/mL penicillin at densities comprised between 0.2 and 1 x 106 
cells/ml. Jurkat culture media was collected each two to three days for exosome isolation. MIN6B1 
cells, a murine insulin-secreting cell line (Lilla et al., 2003), were cultured at a density of 1.5 x 105 
cells/cm2 in DMEM-GlutaMAXTM medium (Invitrogen) containing 25 mM glucose and 4 mM L-
glutamine, and supplemented with 15% fetal calf serum, 70 μM β-mercaptoethanol, 50 μg/mL 
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streptomycin and 50 IU/mL penicillin. All cell lines were cultured at 37°C in a humidified atmosphere 
(5% CO2, 95% air) and tested negative for mycoplasma contamination. 
 
METHOD DETAILS  
Isolation of rodent pancreatic islet cells – Rodent islets were isolated by collagenase digestion of the 
pancreas (Gotoh et al., 1987) followed by Histopaque density gradient to separate them from digested 
exocrine tissue. At the end of the isolation, islets were hand-picked and incubated overnight at 37°C 
in RPMI 1640- GlutaMAXTM medium (Invitrogen) containing 11.1 mM glucose and 2.06 mM L-
glutamine and supplemented with 10% fetal calf serum (Gibco), 10 mM Hepes, pH 7.4, 1 mM sodium 
pyruvate, 100 μg/mL streptomycin and 100 IU/mL penicillin. Dissociated islet cells were obtained by 
incubating the islets in Ca2+/Mg2+ free phosphate buffered saline, 3 mM EGTA and 0.002% trypsin 
for 5 min at 37°C. For some experiments, rat islet cells were separated by Fluorescence-Activated Cell 
Sorting (FACS) based on β-cell autofluorescence, as previously described (Jacovetti et al., 2015; 
Kohler et al., 2012). Sorted islet cells were seeded on plastic dishes coated with extracellular matrix 
secreted by 804 G rat bladder cancer cells (804 G ECM), as described elsewhere (Parnaud et al., 2008). 
Enrichment of α - and β-cells was evaluated by double immunofluorescence staining using polyclonal 
guinea pig anti-insulin (dilution 1:100, A0564, Dako) and polyclonal mouse anti-glucagon (dilution 
1:1000, Abcam Ab10988) primary antibodies and goat anti-guinea pig Alexa-Fluor-488 and goat anti-
mouse Alexa-Fluor-555 (diluted 1:500, Molecular Probes, Thermofisher A11073 and A21422, 
respectively) secondary antibodies. On average, β-cell fractions contained 98.1 ± 2.2% insulin-positive 
cells and 1.4 ± 1.5% glucagon-positive cells and α-cell-enriched fractions contained 5.2 ± 3.5% 
insulin-positive cells and 91.2 ± 4.3% glucagon-positive cells.  
T lymphocyte isolation and culture – Mouse T effector cells were purified from lymphoid tissues of 
8 weeks-old NOD/ShiLtJ mice, or miR-155KO mice (or wild type control littermates) using anti-CD4 
and anti-CD25 coated beads (Miltenyi Biotec). Human CD4+ T cells were obtained from 3 anonymous 
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donors that gave informed consent in accordance with the US National Institutes of Health guidelines. 
Briefly, buffy coats were purchased from the Blood Transfusion Center in Lausanne, Switzerland. 
Peripheral blood mononuclear cells were isolated by density centrifugation over a Ficoll-Hypaque 
gradient (Amersham Bioscience) and washed three times. CD4+ T cells were enriched from purified 
mononuclear cells by positive selection using anti-CD4 magnetic microbeads (Miltenyi Biotec). After 
isolation, murine CD4+/CD25- T cells and human CD4+ T cells were incubated in RPMI 1640-medium 
supplemented with 10% fetal calf serum (previously depleted from serum-exosomes), 100 μg/mL 
streptomycin and 100 IU/mL penicillin and were stimulated for 72h with 20 ng/ml IL-12 and 200 
UI/ml IL-2 (R&D system Europe) and Dynabeads T-activator CD3/CD28 (bead-to-cell ratio of 1) 
(Invitrogen). After three days, media and cells were collected for exosome isolation and/or RNA 
extraction.  
Exosome isolation and quantification – Exosomes were isolated by ultra-centrifugation as described 
previously (Lasser et al., 2012). Briefly, the culture media (depleted from serum-exosomes) of Jurkat 
cells or primary T cells were collected and centrifuged first at 300 x g for 3 min to pellet cells and then 
at 2000 x g for 10 min to discard dead cells. Supernatants were centrifuged at 10’000 x g for 30 min 
to remove cell debris. Exosomes were then isolated from the supernatant by ultracentrifugation at 
100’000 x g for 2h. The pellet containing the exosomes was washed with PBS and re-centrifuged at 
100’000 x g for 2h. Exosomes were collected in a minimal volume of PBS. The same volume of PBS 
(without exosomes) was added to control experimental conditions. Protein concentration was 
determined by Bradford assay (BioRad). Recipient MIN6B1 or islet cells were incubated with 50 
µg/ml of exosome preparation previously passed on a 0.45 µm filter (Figliolini et al., 2014; Guay et 
al., 2015). The amount of vesicles added to the recipient cells was estimated using the FluoroCet 
exosome quantification kit (System Biosciences), which is based on the measurement of the esterase 
activity associated with exosomes. According to these measurements, the recipient cells were exposed 
to exosome concentrations of about 0.8x1011/ml for exoT, 0.7x1011/ml for exoNOD and 2 x1011/ml for 
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exo-hT. These concentrations are within the same range as those previously reported in murine and 
human plasma samples (Matsumoto et al., 2016; Thomou et al., 2017).  
Electron microscopy – Suspensions were adsorbed on 200 Mesh Cupper grids coated with forvmar-C 
for 2 min at RT. The grids were then stained using 2% phosphotungstic acid for 2 min and observed 
on a transmission electron microscope (Jeol 1400 JEM, Tokyo, Japan) equipped with a Gatan camera 
(Orius 600) and Digital Micrograph Software. 
Nanosight analysis – Exosome size distribution was measured by Nanoparticle Tracking Analysis 
using the NanoSight system (NanoSight, UK). The device measures the Brownian motion of particles 
whose speed of motion, or diffusion coefficient (Dt), is related to particle size through the Stokes-
Einstein equation (Soo et al., 2012).  
Western blot – Proteins from exosome samples or from cellular lysates were migrated on 10% SDS-
PAGE gels. Following electrophoresis, proteins were transferred onto PVDF membranes and blocked 
at room temperature in Tris-buffered saline/0.3% Tween20 containing 4% of BSA. The membranes 
were then incubated overnight at 4 °C with CD81 (sc-166028), Alix (sc-49268) or TSG101 (sc-6037) 
antibodies (Santa Cruz Biotechnology) diluted 1/1000 in 1% BSA. The bands were detected by 
chemiluminescence (Pierce) after incubation with a horseradish peroxidase-conjugated secondary 
antibody (Bio-Rad). 
Image stream analysis – Exosomes from Jurkat cells were labelled with 1µM of the lipophilic dye 
DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt, 
Molecular Probes) during the last ultracentrifugation (2h at 100’000 x g). The labelled-exosome pellet 
was washed twice in PBS before another round of ultracentrifugation (2h at 100’000 g). MIN6B1 cells 
or dissociated rat islet cells were incubated overnight in the presence of DiD-labelled exoT, before 
being analyzed on Amnis ImageStreamX Mark II (Merk Millipore).  
RNase treatment – Exosome preparations were re-suspended in 300 μl PBS and spiked with 20 ρmol 
of a synthetic oligonucleotide corresponding to the mature sequence of miR-29a (Exiqon).  Samples 
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were then divided into four aliquots and treated or not with 1% Triton X-100 (Sigma) and incubated 
with or without RNase A (0.5 U) and RNase T1 (15 U) (Ambion) for 30 min at 37°C before RNA 
extraction. 
RNA assays – RNA was extracted from exosomes, Jurkat, MIN6B1 or islet cells using the miRNeasy 
micro kit (Qiagen). Mature miRNA levels were measured using the miRCURY LNATM Universal RT 
microRNA PCR kit (Exiqon) starting from 200 ng of RNA. Cellular miRNA levels were normalized 
to miR-7 levels, a miRNA highly expressed in β-cells and not modified under the studied conditions. 
For mRNA measurement, RNA samples were treated with DNase prior to analysis. Profiling of mRNA 
was performed by Arraystar (MD, USA) using Agilent Technologies and Agilent GeneSpring GX 
v12.1 software for data analysis. Gene expression levels were measured by qPCR using miScript II 
RT and SYBR Green PCR kits (Qiagen) and results were normalized to 18S rRNA and Hprt. Finally, 
GFP levels were assessed using SYBR Green PCR Master Mix (Life Technologies) with primers 
specific for GFP and normalized to Gapdh levels. Primer sequences are provided in Table S5. All 
qPCR measurements were performed in triplicates and expression levels of miRNAs and mRNAs were 
analyzed using the 2-ʌʌC(T) method. 
Transfection of insulin-secreting cells – MIN6B1 or dispersed rat islet cells were transfected using 
Lipofectamine 2000TM (Invitrogen) with RNA oligonucleotide duplexes (Exiqon) corresponding to the 
mature miRNA sequence (overexpression) or with single-stranded miRCURY LNA inhibitors 
(Exiqon) that specifically block the miRNAs (down-regulation). A control miRNA mimic or the 
control miRCURY LNA inhibitor (Exiqon) were used as negative controls for miRNA overexpression 
and down-regulation, respectively.  
Insulin secretion and content – After incubation for 72h in the presence of exosomes (or control PBS), 
MIN6B1 or dissociated rat islet cells were pre-incubated for 30 min at 37°C in Krebs-Ringer 
bicarbonate buffer (KRBH) containing 25 mM HEPES, pH 7.4, 0.1 % BSA (Sigma-Aldrich) and 2 
mM glucose. The cells were then incubated for 45 min in KRBH containing 0.5% BSA and 2 or 20 
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mM glucose. At the end of the incubation period, media were collected and total cellular insulin 
contents recovered in acid-ethanol (0.2 mM HCl in 75% ethanol). Insulin levels were measured using 
an insulin enzyme immunoassay kit (SPI-Bio). All experiments were performed in triplicates.  
Cell death assays – MIN6B1 and dissociated islet cells were incubated for 72h in presence of T cell 
exosomes with or without 0.1mM of the pan caspase inhibitor Z-VAD-FMK (R&D systems). At the 
end of the incubation, 1 μg/ml Hoechst 33342 (Invitrogen) was added for 1-2 min. Cells displaying 
pycnotic nuclei were scored under fluorescence microscopy (AxioCam MRc5, Zeiss). A minimum of 
thousand cells were counted per condition. TUNEL staining on human β-cells was performed 48h after 
exposure to exo-hT using the In Situ Cell Death Detection Kit (Roche) combined to FLEX polyclonal 
guinea pig anti-insulin (dilution 1:10, IR00261-2, Dako) followed by incubation with fluorescently-
labeled goat anti-guinea-pig AlexaFluor 555 antibody (dilution 1:400, A21435, Thermofisher). NFκB 
translocation was assessed in MIN6B1 cells after exposure for 48h to exoT or for 24h to pro-
inflammatory cytokines (30 ng/ml INFγ, 10 ng/ml TNFα and 0.1 ng/ml IL-1β). Briefly, MIN6B1 cells 
cultured on coverslips were fixed, permeabilized and incubated with a mouse anti-NFκB p65 antibody 
(dilution 1:100, sc-372, Santa Cruz Biotechnology) followed by goat anti-mouse Alexa Fluor 488 
antibody (A-11029, Invitrogen). Cell nuclei were stained with Hoechst 33342 (1 μg/ml, Invitrogen). 
Coverslips were mounted on microscope glass slides with Fluor-Save mounting medium (VWR 
International SA) and were visualized with a Zeiss Axiovision fluorescence microscope. Experiments 
were performed in single replicates.  
Luciferase – MIN6B1 cells were transfected using Lipofectamine 2000TM (Invitrogen) with a pGL3 
plasmid containing the hsa-miR-155 binding sequence in the 3’UTR (Skalsky et al., 2007) and the 
psicheck1 vector (Promega). After 7h, culture media of transfected MIN6B1 was changed and exoT 
was added for 48h or 72h. Luciferase activities were measured using the Dual-Luciferase Reporter 
Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity to 
minimize experimental variabilities. Experiments were performed in triplicates.    
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Generation of viral vectors – The dsAAV-RIP-GFP (AAV-control) was constructed on the backbone 
of the dsAAV8 plasmid (Nathwani et al., 2006) by replacing the original LP1 promotor and FIX coding 
sequences with two multiple cloning sites and inserting the coding sequences for the Rat Insulin 
promotor (RIP) (Addgene plasmid 15029) and green fluorescent protein (GFP) into the multiple 
cloning site, using the PstI-AccIII and EcoRI-NotI restriction sites. For the construction of the dsAAV-
RIP-GFP-sponge (AAV-sponge), the interrupted palindromic SanDI (Fermentas) restriction site was 
used to insert miRNA binding sites for miR-142-3p/-5p, miR-150 and miR-155 (Table S6) (Kluiver et 
al., 2012). Viral particles were generated by a triple transfection of HEK293 cells using the 25 kDa 
linear polyethylenimine (Polysciences Inc) transfection method (Reed et al., 2006). AAV particles 
were purified by iodixanol gradient centrifugation as previous described (Zolotukhin et al., 1999). 
Viral titers were determined by qPCR with specific primers for the RIP and GFP.  
In vivo experiments – Female NOD/ShiLtJ mice were injected intraperitoneally (I.P.) with 150 µl PBS 
containing 1 x1012 viral genome particles at the age of 4 weeks. Blood glucose levels were measured 
once per week on restrained, un-anesthetized animals through tail vein bleeds with a glucometer and 
test strips (Life Scan). NOD mice were diagnosed as diabetic if blood glucose levels above 14 mM on 
2 consecutive days. Glucose tolerance test was performed by injecting I.P. 1.5g glucose per kg of body 
weight on 4 hour fasted NOD mice of 10 weeks of age, from the diabetes incidence cohort. 
Experiments were not performed blinded. One mouse from the AAV-ctl group was excluded and 
euthanized at 13 days after injection as it met ethical endpoints (loss of more than 15% of body weight 
after injection and showed signs of discomfort).   
Histology and immunohistochemistry – Formalin-fixed pancreatic tissues were embedded in paraffin 
using standard techniques. 4-μm sections were deparaffinized, rehydrated, and incubated with 
blocking solution. Sections were incubated overnight at 4°C with antibodies against GFP (Life 
Technologies), followed by signal amplification using the TSA Fluorescein system (Perkin Elmer) or 
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with CD3 antibody (dilution 1:500, A0452, Dako) followed by the fluorescently-labeled secondary 
antibody goat anti-rabbit AlexaFluor-555 (dilution 1:200, A21428, Molecular Probes, Thermofisher). 
Insulitis score was evaluated by Hematoxylin-Eosin staining of formalin-fixed paraffin embedded 
pancreata sections. A score ranging from 0 to 3 was assigned to each identified islet by manual bright 
field microscope visualization (0: intact islet; 1: peri-insulitic islet; 2: <50% infiltrated islet area; 3: > 
50% infiltrated islet area) (Figure S8).  
Immunofluorescence analysis was performed to quantify insulin, glucagon and Cxcl10 positive 
volume. 5µm formalin-fixed paraffin embedded pancreata sections were subjected to double or triple 
immunofluorescence staining using respectively polyclonal guinea pig anti-insulin (dilution 1:500, 
A0564, Dako), monoclonal mouse anti-glucagon (dilution 1:300, MAB1249, R&D Systems) and 
polyclonal rabbit anti-murine CXCL10 (dilution 1:25, 500-P129, Peprotech); fluorescently-labeled 
secondary antibodies were goat anti-guinea pig Alexa-Fluor 488 (dilution 1:500, A11073, Molecular 
Probes, Thermofisher), goat anti-mouse 647 (dilution 1:500, A21236, Molecular Probes, 
Thermofisher) or goat anti-rabbit Alexa-Fluor 594 conjugated (dilution 1:500, A11037, Molecular 
Probes, Thermofisher). Stained sections were imaged and analyzed using Leica Sp5 confocal 
microscopy. Five different focal planes for each identified islet were scanned at 40X magnification. 
The analysis of positive insulin and CXCL10 volume (µm3) and CXCL10-insulin and CXCL10-
glucagon colocalization rate (%) was quantified using Volocity 6.3 software (Perkin Elmer) by 
measuring the quantity of insulin and CXCL10 positive fluorescent voxels signal in five different focal 
planes of each scanned islet and by measuring the ratio between double positive voxels CXCL10-
insulin and CXCL10-glucagon on total insulin and glucagon positive voxels for each scanned islet.  
Immunofluorescence analysis to quantify insulin, glucagon and FoxP3+ cells, was performed by  triple 
immunofluorescence staining with polyclonal guinea pig anti-insulin (dilution 1:500, A0564, Dako), 
monoclonal mouse anti-glucagon (dilution 1:300, MAB1249, R&D Systems) and rat monoclonal anti-
murine FoxP3, FITC conjugated (dilution 1:100, 11-5773-82, eBioscience); fluorescent labeled 
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secondary antibodies goat anti-guinea pig Alexa Fluor 405 conjugated (dilution 1:500, Ab175678, 
Abcam), goat anti-mouse 594 conjugated (dilution 1:500, A11032, Molecular Probes, Thermofisher), 
Rabbit anti-fluorescein 488 conjugated (dilution 1:80, A11090, Molecular Probes, Thermofisher) and 
tertiary antibody goat anti-rabbit 488 conjugated (dilution 1:200, A11034, Molecular Probes, 
Thermofisher), were used. Stained sections were imaged and analyzed using Leica Sp5 confocal 
microscopy as described above and FoxP3+ cells were quantified through manual cell count. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Data are expressed as mean ± SD. Statistical significance was determined using parametric unpaired 
two-tailed Student’s t-test or, for multiple comparisons, with one-way analysis of variance (ANOVA) 
of the means, followed by post-hoc Dunnett or Tukey test, or unparametric Mann-Whitney U test 
(Graph Pad Prism6). The percentage of nondiabetic mice was calculated by Kaplan–Meier survival 
analysis and were compared using the Log rank (Mantel-Cox) test. P values less than 0.05 (p < 0.05) 
were considered statistically significant. 
DATA AND SOFTWARE AVAILABILITY 
The accession number for the genomic data reported in this paper is Gene Expression Omnibus: 
GSE92439.  
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Alix 1:1000 Santa Cruz 
Biotechnology 
Cat# sc-49268 
RRID: AB_2268130 
CD3 1:500 Dako Cat# A0452 
RRID: AB_2335677 
CD4+ CD25+ Regulatory T Cell Isolation Kit, mouse Miltenyi Cat#130-091-041 
CD81 1:1000 Santa Cruz 
Biotechnology 
Cat# sc-166028 
RRID: AB_2275895 
CXCL10 1:25 Peprotech Cat# 500-P129 
RRID: AB_147769 
Fluorescein 1:80 Thermofisher Rabbit; Alexa 488; 
Cat# A11090 
RRID: AB_221562 
FoxP3, FITC conjugated 1:100 eBioscience Cat# 11-5773-82 
RRID: AB_465243 
Glucagon 1:1000 (ICC) Abcam Cat# Ab10988 
RRID: AB_297642 
Glucagon 1:300 (IHC) R&D Systems Cat# MAB1249 
RRID: AB_2107340 
IgG (Guinea Pig) 1:500 Abcam Goat; Alexa 405; 
Cat# Ab175678 
IgG (Guinea Pig) 1:500 Thermofisher Goat; Alexa 488; 
Cat# A11073 
RRID: AB_142018 
IgG (Guinea Pig) 1:400 Thermofisher Goat; Alexa 555; 
Cat# A21435 
RRID: AB_1500610 
IgG (Mouse) 1:500 Thermofisher Goat; Alexa 488; 
Cat# A11029 
RRID: AB_138404 
IgG (Mouse) 1:500 Thermofisher Goat; Alexa 555; 
Cat# A21422 
RRID: AB_141822 
IgG (Mouse) 1:500 Thermofisher Goat; Alexa 594; 
Cat# A11032 
RRID: AB_141672 
IgG (Mouse) 1:500 Thermofisher Goat; Alexa 647; 
Cat# A21236 
RRID: AB_ 2535805 
IgG (Rabbit) 1:200 Thermofisher Goat; Alexa 488; 
Cat# A11034 
RRID: AB_ 2576217 
IgG (Rabbit) 1:200 Thermofisher Goat; Alexa 555; 
Cat# A21428 
RRID: AB_141784 
IgG (Rabbit) 1:500 Thermofisher Goat; Alexa 594; 
Cat# A11037 
RRID: AB_2534095 
Key Resource Table
Insulin 1:100 (ICC) or 1:500 (IHC) Dako Cat# A0564 
RRID: AB_10013624 
Insulin 1:10 (human) Dako Cat# IR00261-2 
NFκB p65 1:100 Santa Cruz 
Biotechnology 
Cat# sc-372 
RRID: AB_10013624 
TSG101 1:1000 Santa Cruz 
Biotechnology 
Cat# sc-6037 
RRID: AB_2208099 
Bacterial and Virus Strains 
dsAAV8-RIP-GFP-sponge This paper N/A 
dsAAV8-RIP-GFP-control This paper N/A 
Biological Samples 
Non-diabetic; 53 years; M; 27.2 BMI; human islets (80% 
purity, 90% viability) (organ donor) 
CEED in Strasbourg, 
France 
N/A 
Non-diabetic; 39 years; F; 31.4 BMI; human islets (70% 
purity, 90% viability) (organ donor) 
CEED in Strasbourg, 
France 
N/A 
Non-diabetic; 43 years; F; 34.0 BMI; human islets (90% 
purity, 95% viability) (organ donor) 
Tebu-Bio HP-18157-01 
Non-diabetic; 50 years; F; 19.6 BMI; human islets (80% 
purity, 95% viability) (organ donor) 
CEED in Strasbourg, 
France 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
DiD (Vybrant™ Multicolor Cell-Labeling Kit) Molecular Probes Cat# V22889 
Dynabeads T-activator CD3/CD28, human Invitrogen Cat# 11132D 
Dynabeads T-activator CD3/CD28, mouse Invitrogen Cat# 11456D 
Hoechst 33342 Invitrogen Cat# H21492 
IFNγ, mouse R&D system Europe Cat# 485-MI 
IL-1β, mouse Peprotech Cat# 211-11B 
IL-2, human R&D system Europe Cat# 200-02 
IL-2, mouse R&D system Europe Cat# 212-12 
IL-12, mouse R&D system Europe Cat# 210-12 
pan caspase inhibitor Z-VAD-FMK R&D system Europe Cat# FMK001 
TNFα Peprotech Cat# 315-01A 
Critical Commercial Assays 
FluoroCet exosome quantification kit System Biosciences Cat# FCET96A-1 
Deposited Data 
Raw microarray data This paper GSE92439 
Experimental Models: Cell Lines 
Jurkat cells, J77 clone 20 O. Acuto Rebeaud et al., 2008 
MIN6B1 cell line PA Halban Lilla et al., 2003 
Experimental Models: Organisms/Strains 
Wistar Han IGS Rat Charles River Cat# 2308816 
RRID:RGD_230881
6 
JAX™ NOD/ShiLtJ Mice Charles River Cat# JAX:001976 
RRID:IMSR_JAX:00
1976 
NOD.CB17/Prkdcscid/scid/Rj Janvier Cat# SM-NOD 
B6.Cg-Mir155tm1Rsky/J Jackson Cat# JAX:007745 
RRID:IMSR_JAX:00
7745 
C57Bl/6N mice Janvier JAX:005304 
RRID:IMSR_JAX:00
5304 
Oligonucleotides 
miRCURY LNA inhibitor Control (Neg A) Exiqon Cat# 199004-00 
hsa-miR-142-3p miRCURY LNA miRNA Inhibitor Exiqon Cat# 410060-00 
hsa-miR-142-5p miRCURY LNA miRNA Power Inhibitor Exiqon Cat# 426805-00 
hsa-miR-155-5p miRCURY LNA miRNA Inhibitor Exiqon Cat# 410078-00 
mmu-miR-155-5p miRCURY LNA miRNA Inhibitor Exiqon Cat# 411222-00 
Negative Control 4 miRCURY LNA miRNA Mimic Exiqon Cat# 479903-001 
hsa-miR-29a miRCURY LNA miRNA Mimic Exiqon Cat# 472650 -001 
hsa-miR-142-3p miRCURY LNA miRNA Mimic Exiqon Cat# 470805-001 
hsa-miR-142-5p miRCURY LNA miRNA Mimic Exiqon Cat# 470908-001 
mmu-miR-155 miRCURY LNA miRNA Mimic Exiqon Cat# 470919-001 
hsa-miR-7-5p PCR primers Exiqon Cat# 205877 
hsa-miR-29a-3p PCR primers Exiqon Cat# 204698 
hsa-miR-142-3p PCR primers Exiqon Cat# 204291 
hsa-miR-142-5p PCR primers Exiqon Cat# 204722 
hsa-miR-146a PCR primers Exiqon Cat# 204688 
hsa-miR-150-5p PCR primers Exiqon Cat# 204660 
hsa-miR-155-5p PCR primers Exiqon Cat# 204308 
mmu-miR-155-5p PCR primers Exiqon Cat# 205930 
Recombinant DNA 
psicheck1 vector - hsa-miR-155 binding sequence in the 
3’UTR 
R. Renne Skalsky et al. 2007 
psicheck1 vector - ctl Promega Cat#: C8011 
Software and Algorithms 
Volocity 6.3 software Perkin Elmer RRID:SCR_002668 
Graph Pad Prism 6 Graph Pad software https://www.graphpa
d.com/scientific-
software/prism/ 
AB
Figure S1: miRNA levels in exosomes, T lymphocytes and pancreatic islet
cells. Related to Figure 1. miRNA levels were measured by qPCR from 200 ng of
RNA, from A) NOD T lymphocytes (white bars) and FACS-sorted beta-cells (black
bars), B) exoT and C) exoNOD. Results were calculated using the 2-ʌC(T) method
and are presented as Relative Fluorescent Units (RFU) in log scale (n=3 indep.
exp.). * p<0.05 by Student’s t-test.
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BC
Figure S2: Transfer of exosomal miRNAs to MIN6B1 cells. Related to Figure 3.
A) Mature miRNA sequences. B-C) Levels of the indicated miRNAs in MIN6B1 cells
incubated for 72h with exoT (n=5-7 indep. exp.). D-H) T cells were isolated from the
spleen of wild-type (WT) or KO miR-155 (KO) mice and cultured ex vivo for exosome
isolation. miR-155 expression in D) T cells or E) exosomes from WT or miR-155 KO
mice (n=3 indep. exp.). F-H) MIN6B1 cells were incubated with exosomes from WT or
KO T cells (exoWT or ExoKO) for 72h prior to RNA extraction and measurement of
miR-155 (F), miR-142-3p (G) and miR-142-5p (H) (n=3 indep. exp.). miRNA levels
were measured by qPCR, normalized to miR-7 and expressed as fold changes over
Ctl or as RFU (Relative Fluorescent Unit) if not detected (ND) in Ctl condition. miR-
155 expression in T cells and in exosomes are presented as CT. **Significantly
different from Ctl condition, p<0.01 by Student’s t-test.
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Figure S3: Effects of exoT on beta-cell function and survival. Related to Figure 3.
Dispersed rat islet (A-B) or MIN6B1 (C-H) cells were incubated for 72h without
treatment (NT), with control supernatant (Ctl) or with exosomes isolated from culture
media of Jurkat cells (exoT). At the end of the incubation period, A,C) insulin release in
response to 2 or 20 mM glucose (2-20G) or to 35 mM KCl, and B,D) insulin content,
were measured by ELISA (n=3 indep. exp.). E-G) Apoptosis was assessed by scoring
the cells displaying pycnotic nuclei upon Hoechst staining, with or without the pan-
caspase inhibitor zVAD (E: n=6, F: n=4, G: n=3 indep. exp.). H) miR-142-3p and miR-
142-5p levels were measured by qPCR and normalized to miR-7 (n=4). *Significantly
different from Ctl condition # Significantly different from ExoT condition (without Z-
VAD). *p<0.05 or **,## p<0.01 by Student’s t-test or, for multiple comparisons, by one-
way Anova, Dunnett’s post-hoc test.
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Figure S4: Signaling pathways activated in response to exosomes. Related to Figure
5. A) KEGG pathway enrichment analysis of genes differentially expressed in mouse islet
cells incubated with exoNOD. The bars show the Enrichment score (-log10 p-value) of the
indicated pathways in the array data set. Modified Fisher’s exact test (EASE cutoff p<0.05)
was used to estimate the false discovery rate (FDR) and the thresholds to select
significantly enriched KEGG pathways (n=3 indep. exp.). B) Representative pictures of
NFκB translocation to the nucleus. MIN6B1 cells were incubated with exoT for 72h or a mix
of pro-inflammatory cytokines (cyt.: IFNγ, TNFα and IL-1β) for 24h, or were transfected
with miRNA mimics leading to overexpression of miR-142-3p, miR-142-5p and miR-155 for
48h (Mimics). At the end of the incubation period, cellular localization of NFκB was
determined by immunostaining. White arrows indicate positive cells with NFκB
predominantly inside the nucleus. Scale bar = 10µm.
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Figure S5: Effect of miRNA overexpression on beta-cell function. Related to
Figure 6. Dispersed rat islet (A-B) or MIN6B1 (C-D) cells were transfected with the
indicated miRNA mimic. Expression levels or functional assays were performed 48h
post-transfection. A,C) miRNA levels were measured by qPCR, normalized to miR-7
and expressed as fold change over Ctl (n=3). B) Insulin content was measured by
ELISA (n=3-4 indep.exp.). D) Apoptosis was assessed by scoring MIN6B1 cells
displaying pycnotic nuclei upon Hoechst staining. Cytokine treatment (Cyt) was used
as a positive control (n=4-7). *p<0.05 **p<0.01 by Student’s t-test.
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Figure S6: Downregulation of miRNAs using anti-miRs and their effect on beta-
cell survival. Related to Figure 6. Dispersed rat islet cells were transfected with
anti-miR to specifically downregulate A,E) miR-142-3p (n=4), B,F) miR-142-5p (n=4),
C,G) hsa-miR-155 (n=4) or D) mmu-miR-155 (n=4 indep. exp.) and were incubated
with A-D) exoT for 72h or E-G) a cytokine mix for 24h (black bars). A-D) miRNA levels
in islet cells were measured by qPCR. The data are expressed as fold changes
versus the anti-ctl, not treated, condition. Since hsa-miR-155 is not detected in
untreated cells, results are expressed as relative fluorescence unit (RFU, derived
from qPCR CT). ND= below qPCR detection limit. E-G) Apoptosis was determined by
scoring the cells displaying pycnotic nuclei upon Hoechst staining. Data are
expressed as fold changes versus the anti-ctl, not treated, condition. *,#p<0.05, **,##
p<0.01 by one-way Anova, Dunnett’s post-hoc test.
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Figure S7: Characterization of female NOD mice injected with AAV-control or AAV-
sponge. Related to Figure 7. 4 week-old female NOD mice were injected
intraperitoneally with an AAV-control (Ctl) or with an AAV producing the microRNA sponge
(Sp). A-C) GFP expression produced by the AAV construct was detected in NOD mice of
8 weeks of age on pancreatic sections by immunostaining (A,C), or (B) in isolated islets
by qPCR (normalized to GAPDH) (n=6). C) GFP expression (Green) was not detected in
immune cells marked with CD3 antibody (Red). Nuclei were stained with Dapi (Blue). D)
Body weight and E) plasma glucose level were measured at 8 weeks of age (n=7). F)
Intraperitoneal glucose tolerance test (1.5g/kg) was performed on 4h fasted NOD female
at 10 weeks of age (n=10).
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Figure S8: Infiltration and inflammation status of islets of NOD mice injected
with AAV-control or AAV-sponge. Related to Figure 7.
A) Representative images of insulitis score classification analysis in NOD mice.
Hematoxylin/Eosin staining on FFPE NOD mouse pancreata sections showing:
Score-0: intact and not infiltrated islets, Score-1: islets with peri-insulitis, Score-2: islet
with moderate insulitis with immune cells within less than 50% of islet area, and
Score-3: islet with heavy insulitis with immune cells within more than 50% of islet
area. Scale bar 100µm. B) Insulitis score measured in the pancreases of 8 weeks old
AAV-control (Ctl) or AAV-sponge (Sp) injected mice (n=7 mice per group). C) Number
of FoxP3+ T reg cells (green, arrow) per infiltrate measured in pancreases of NOD
mice injected with AAV-sponge protected (Sp-Prot) or not (Sp-NP) from diabetes
development, at the time of sacrifice. (insulin marked in blue and glucagon in red). **
p < 0.01 by Mann-Whitney U test.
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Table S1: Specificity of human versus mouse miR-155 primer. Related to Figure 3.
hsa-miR-155 and mmu-miR-155 level were measured from 200ng of indicated sample.
Origin Name CT RFU (2
-ct
) CT RFU (2
-ct
)
Human exoT ND - 28.16 3.33E-09
Jurkats ND - 27.06 7.15E-09
Islets ND - 26.03 1.46E-08
Rodent Rat islets 31.20 4.06E-10 ND -
Mouse islets 30.50 6.60E-10 ND -
MIN6B1 cells 34.25 4.91E-11 ND -
ND: under the detection limit of the qPCR (CT>37)
mmu-miR-155 hsa-miR-155Samples
Table S2:  Effect of exoNOD on islet cell gene expression. Related to Figure 5.
Dispersed mouse islet cells were incubated without (Ctl) or with exoNOD for 72h. Analysis of mRNA expression was then performed by microarray (n=3). Genes displaying a fold change > 2 and a nominal p-value < 0.05 are presented in this Table.
Gene 
Symbol
Description
Genbank 
Accession No
Fold 
Change
P-value FDR Regulation group-Exo group-Ctl group-Exo group-Ctl
Upregulated
Ear12 Eosinophil-associated, ribonuclease A family, member 12 NM_001012766 15.24 0.0118801 0.353 up 148.13 5.56 6.54 2.61
Pf4 Platelet factor 4 NM_019932 7.05 0.015727 0.354 up 574.64 69.88 8.94 6.13
Zfy1 Zinc finger protein 1, Y linked NM_009570 6.52 0.0203802 0.359 up 49.91 5.20 5.19 2.49
Ccl24 Chemokine (C-C motif) ligand 24 NM_019577 6.22 0.0215034 0.360 up 137.29 22.19 6.97 4.33
Reg3b Regenerating islet-derived 3 beta NM_011036 6.10 0.0259424 0.367 up 64.06 7.50 5.51 2.91
Ear1 Eosinophil-associated, ribonuclease A family, member 1 NM_007894 5.71 0.0304683 0.376 up 52.82 5.78 5.12 2.61
Ear2 Eosinophil-associated, ribonuclease A family, member 2 NM_007895 5.05 0.0307279 0.377 up 278.58 37.41 7.69 5.35
Pdcd1lg2 Programmed cell death 1 ligand 2 NM_021396 4.47 0.012026 0.353 up 219.06 46.58 7.68 5.52
Grem1 Gremlin 1 NM_011824 4.43 0.0051617 0.324 up 38.97 7.65 5.10 2.96
Ccl2 Chemokine (C-C motif) ligand 2 NM_011333 4.25 0.0479823 0.400 up 2696.45 740.89 11.32 9.24
Mrc1 Mannose receptor, C type 1 NM_008625 3.89 0.0042547 0.315 up 66.66 14.13 5.90 3.94
Ccl7 Chemokine (C-C motif) ligand 7 NM_013654 3.85 0.0279532 0.372 up 498.58 133.18 8.89 6.94
Pdpn Podoplanin NM_010329 3.83 0.0183558 0.354 up 907.44 244.77 9.79 7.85
Serpina3g Serine (or cysteine) peptidase inhibitor, clade A, member 3G NM_009251 3.59 0.0196062 0.357 up 1377.21 367.88 10.34 8.50
Tnnt2 Troponin T2, cardiac NM_011619 3.49 0.0303066 0.376 up 29.04 7.55 4.62 2.82
Ifng Interferon gamma NM_008337 3.13 0.0065303 0.327 up 30.62 7.38 4.71 3.06
Klra15 Killer cell lectin-like receptor, subfamily A, member 15 NM_013793 3.11 0.0021235 0.289 up 17.93 5.00 3.98 2.34
F10 Coagulation factor X NM_007972 3.09 0.0458147 0.396 up 215.59 69.24 7.65 6.02
Apol7c Apolipoprotein L 7c NM_175391 3.03 0.0032293 0.299 up 63.07 17.13 5.84 4.24
Dlx5 Distal-less homeobox 5 NM_010056 3.02 0.0121578 0.353 up 103.25 27.59 6.51 4.92
Ereg Epiregulin NM_007950 3.00 0.0074262 0.337 up 78.52 21.38 6.13 4.54
Timp1 Tissue inhibitor of metalloproteinase 1 NM_001044384 2.94 0.0171777 0.354 up 4303.92 1401.02 11.99 10.44
Rnase10 Ribonuclease, RNase A family, 10 NM_029145 2.91 0.0021479 0.289 up 378.02 114.24 8.47 6.93
Cck Cholecystokinin NM_001284508 2.80 0.005592 0.325 up 529.91 170.79 8.97 7.48
Gfra2 Glial cell line derived neurotrophic factor family receptor alpha 2 NM_008115 2.80 0.011636 0.353 up 79.60 22.38 6.12 4.63
Ms4a1 Membrane-spanning 4-domains, subfamily A, member 1 NM_007641 2.78 0.0260844 0.367 up 35.31 9.77 4.91 3.44
Kank4 KN motif and ankyrin repeat domains 4 NM_172872 2.72 0.0055869 0.325 up 35.87 10.63 5.00 3.56
Cst7 Cystatin F (leukocystatin) NM_009977 2.67 0.0214243 0.360 up 45.48 14.59 5.36 3.94
Speer4c Spermatogenesis associated glutamate (E)-rich protein 4c NM_001281511 2.67 0.0241672 0.364 up 116.55 35.72 6.70 5.28
Tspan10 Tetraspanin 10 NM_145363 2.65 0.0378119 0.387 up 18.45 5.35 3.89 2.49
Defb45 Defensin beta 45 NM_001037752 2.58 0.0147662 0.354 up 112.79 35.88 6.66 5.29
Olfr1410 Olfactory receptor 1410 NM_146491 2.55 0.0099897 0.349 up 672.83 236.37 9.30 7.95
Egr2 Early growth response 2 NM_010118 2.54 0.0227117 0.361 up 270.40 98.23 8.00 6.65
H2-Eb2 Histocompatibility 2, class II antigen E beta2 NM_001033978 2.54 0.0097198 0.348 up 130.00 44.23 6.91 5.57
Ccbe1 Collagen and calcium binding EGF domains 1 NM_178793 2.53 0.0104507 0.349 up 111.91 37.54 6.68 5.34
Dbh Dopamine beta hydroxylase NM_138942 2.48 0.0096035 0.348 up 37.53 11.61 5.02 3.71
Olfr1198 Olfactory receptor 1198 NM_207567 2.48 0.0062325 0.325 up 78.25 25.71 6.13 4.82
Chil3 Chitinase-like 3 NM_009892 2.47 0.0006986 0.226 up 129.32 44.95 6.92 5.61
Cd300a  CD300A antigen NM_170758 2.46 0.0166578 0.354 up 1338.06 495.83 10.30 8.99
Zfp217 Zinc finger protein 217 NM_001033299 2.46 0.0143316 0.354 up 59.37 19.35 5.72 4.42
Sox3 Sex determining region Y(SRY)-box 3 NM_009237 2.42 0.0005734 0.224 up 14.27 5.00 3.62 2.34
Tpsb2 Tryptase beta 2 NM_010781 2.38 0.0010457 0.248 up 670.40 260.85 9.34 8.08
Golga7b Golgi autoantigen, golgin subfamily a, 7B NM_001141983 2.37 0.049228 0.400 up 1490.35 559.20 10.40 9.16
Ldhc Lactate dehydrogenase C NM_013580 2.36 0.0004425 0.224 up 23.24 7.81 4.38 3.14
Chat Choline acetyltransferase NM_009891 2.36 0.0349162 0.382 up 4214.92 1675.74 11.95 10.71
Gfap Glial fibrillary acidic protein NM_001131020 2.34 0.0180347 0.354 up 33.89 11.52 4.90 3.67
Rarres2 Retinoic acid receptor responder (tazarotene induced) 2 NM_027852 2.33 0.0143987 0.354 up 1883.52 773.19 10.82 9.60
Ptgir Prostaglandin I receptor (IP) NM_008967 2.31 0.005126 0.324 up 102.30 36.92 6.54 5.33
Nwd2 NACHT and WD repeat domain containing 2 NM_177006 2.31 0.0075801 0.340 up 41.38 14.07 5.19 3.98
Nhlh1 Nescient helix loop helix 1 (Nhlh1) NM_010916 2.31 0.0158851 0.354 up 1491.11 595.49 10.46 9.26
Olfr1414 Olfactory receptor 1414 NM_147039 2.30 0.0387261 0.388 up 20.32 7.49 4.15 2.95
Klra4 Killer cell lectin-like receptor, subfamily A member 4 NM_010649 2.30 0.003491 0.307 up 24.60 8.57 4.46 3.26
Raw Intensity Normalized IntensityAnnotations Regulation
Mrgprb3 MAS-related GPR, member B3 NM_207537 2.29 0.0119451 0.353 up 58.11 21.14 5.72 4.53
Mrc2 Mannose receptor, C type 2 NM_008626 2.28 0.0353655 0.382 up 24.12 8.69 4.42 3.23
Map3k13 Mitogen-activated protein kinase kinase kinase 13 NM_172821 2.27 0.0001938 0.188 up 33.93 12.02 4.94 3.76
Adamts14 A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif 14 NM_001081127 2.25 0.0026975 0.296 up 124.60 46.86 6.84 5.68
Lrp2 Low density lipoprotein receptor-related protein 2 NM_001081088 2.23 0.0019692 0.289 up 21.45 7.44 4.23 3.08
March11 Membrane-associated ring finger (C3HC4) 11 NM_177597 2.22 0.0254135 0.366 up 34.73 12.75 4.95 3.80
Ltb Lymphotoxin B NM_008518 2.18 0.0094444 0.348 up 36.10 13.58 5.03 3.90
Skint4 Selection and upkeep of intraepithelial T cells 4 NM_178786 2.17 0.042209 0.391 up 46.43 17.87 5.37 4.25
Arhgef15 Rho guanine nucleotide exchange factor (GEF) 15 NM_177566 2.14 0.0200645 0.357 up 3285.24 1441.61 11.62 10.52
Sp6 Trans-acting transcription factor 6 (Sp6) NM_031183 2.14 0.0210853 0.360 up 464.39 190.00 8.75 7.65
Mbd3l1 Methyl-CpG binding domain protein 3-like 1 NM_028557 2.14 0.0289503 0.374 up 20.65 7.57 4.15 3.06
Olfr432 Olfactory receptor 432 NM_146716 2.14 0.0324781 0.380 up 26.12 9.64 4.52 3.42
Dcaf12l2 DDB1 and CUL4 associated factor 12-like 2 NM_175539 2.12 0.0203415 0.359 up 3304.48 1452.86 11.61 10.52
Tnfrsf9 Tumor necrosis factor receptor superfamily, member 9 NM_011612 2.12 0.024192 0.364 up 4056.77 1800.95 11.92 10.83
Vax2 Ventral anterior homeobox 2 NM_011912 2.12 0.0161331 0.354 up 2366.74 1047.97 11.14 10.05
Fnbp1 Formin binding protein 1 NM_001177648 2.11 0.0243936 0.365 up 4182.22 1862.79 11.96 10.88
Clec1b C-type lectin domain family 1, member b NM_019985 2.10 0.0132953 0.353 up 20.93 8.03 4.23 3.15
Ldha Lactate dehydrogenase A NM_001136069 2.10 0.0023469 0.289 up 1032.44 470.94 9.99 8.92
Sema6d Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D NM_001291000 2.08 0.0206178 0.359 up 2311.89 1054.77 11.11 10.06
Amelx Amelogenin, X-linked NM_009666 2.07 0.0057547 0.325 up 14.41 5.76 3.66 2.61
Hs2st1 Heparan sulfate 2-O-sulfotransferase 1 NM_011828 2.06 0.0224912 0.361 up 1906.89 864.05 10.82 9.78
Scn8a Sodium channel, voltage-gated, type VIII, alpha NM_001077499 2.05 0.0146585 0.354 up 4889.26 2268.17 12.20 11.16
Gxylt2 Glucoside xylosyltransferase 2 NM_198612 2.04 0.0214981 0.360 up 5684.29 2613.52 12.40 11.37
Pdgfra Platelet derived growth factor receptor, alpha polypeptide NM_011058 2.04 0.0166107 0.354 up 79.67 33.54 6.19 5.16
Slc1a4 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 NM_018861 2.04 0.0189431 0.355 up 4149.50 1937.76 11.96 10.94
Cdh11 Cadherin 11 NM_009866 2.04 0.0011886 0.249 up 474.55 214.76 8.84 7.81
Golt1a Golgi transport 1 homolog A (S. cerevisiae) NM_026680 2.03 0.0249666 0.365 up 2023.84 927.02 10.90 9.88
Has2 Hyaluronan synthase 2 NM_008216 2.02 3.38E-05 0.098 up 279.53 123.89 8.06 7.04
Tmprss3 Transmembrane protease, serine 3 NM_001163776 2.02 0.018425 0.354 up 4360.92 2052.55 12.04 11.02
Ifit2 Interferon-induced protein with tetratricopeptide repeats 2 NM_008332 2.02 0.0392298 0.388 up 431.74 195.02 8.66 7.64
Pot1a Protection of telomeres 1A NM_133931 2.02 0.0154162 0.354 up 3916.90 1837.76 11.88 10.87
Bpifc BPI fold containing family C NM_177772 2.02 0.0245966 0.365 up 10564.79 4911.51 13.29 12.28
Hk2 Hexokinase 2 NM_013820 2.02 0.0100239 0.349 up 841.43 392.85 9.67 8.66
Kcna4 Potassium voltage-gated channel, shaker-related subfamily, member 4 NM_021275 2.01 0.0199576 0.357 up 7096.00 3329.32 12.72 11.71
Xdh Xanthine dehydrogenase NM_011723 2.01 0.0020746 0.289 up 186.68 81.80 7.46 6.45
Szrd1 SUZ RNA binding domain containing 1 NM_001025608 2.00 0.0228968 0.361 up 2334.59 1100.89 11.13 10.12
Tfec Transcription factor EC NM_031198 2.00 0.0201551 0.358 up 75.99 31.75 6.10 5.10
Vcam1 Vascular cell adhesion molecule 1 NM_011693 2.00 0.0002573 0.205 up 252.58 112.12 7.91 6.90
Downregulated
Igfbp2 Insulin-like growth factor binding protein 2 NM_008342 6.70 0.0094897 0.348 down 25.47 146.91 4.38 7.13
Lrp4 Low density lipoprotein receptor-related protein 4 NM_172668 3.43 0.0068546 0.330 down 16.46 46.34 3.85 5.63
Ogn Osteoglycin NM_008760 3.35 0.0038083 0.308 down 7.20 19.09 2.64 4.39
Olfr558 Olfactory receptor 558 NM_147093 2.84 0.0418393 0.391 down 29.47 66.86 4.64 6.15
Lama1 Laminin alpha 1 NM_008480 2.57 0.0066104 0.327 down 39.68 85.16 5.15 6.51
Slamf9 SLAM family member 9 NM_029612 2.55 0.0068058 0.330 down 106.74 247.48 6.62 7.97
Cx3cr1 Chemokine (C-X3-C motif) receptor 1 NM_009987 2.40 0.0181431 0.354 down 55.93 120.05 5.66 6.92
Klrb1b Killer cell lectin-like receptor subfamily B member 1B NM_030599 2.34 0.030993 0.378 down 32.65 66.51 4.85 6.08
Cd93 CD93 antigen NM_010740 2.33 0.0131063 0.353 down 92.76 194.21 6.42 7.64
Psd3 Pleckstrin and Sec7 domain containing 3 NM_177698 2.31 0.0036671 0.307 down 23.83 44.82 4.40 5.61
Gdf6 Growth differentiation factor 6 NM_013526 2.25 0.0018827 0.284 down 29.42 54.61 4.71 5.88
Igfbp2 Insulin-like growth factor binding protein 2 NM_008342 2.24 0.0286796 0.374 down 59.80 120.28 5.75 6.91
Apoe Apolipoprotein E NM_009696 2.22 0.0008202 0.244 down 1732.95 3733.75 10.73 11.88
Wisp2 WNT1 inducible signaling pathway protein 2 NM_016873 2.21 0.0311692 0.378 down 234.89 464.16 7.75 8.90
Ctla2b Cytotoxic T lymphocyte-associated protein 2 beta NM_007797 2.06 0.0404583 0.389 down 260.17 496.51 7.92 8.96
Lactbl1 Lactamase beta-like 1 NM_001243262 2.06 0.0427477 0.391 down 9.46 14.35 2.95 3.99
Hpgd Hydroxyprostaglandin dehydrogenase 15 (NAD) NM_008278 2.05 0.0299584 0.375 down 10.42 16.33 3.15 4.19
Srpx Sushi-repeat-containing protein NM_016911 2.05 0.0018271 0.283 down 55.64 97.49 5.66 6.70
Pappa2 Pappalysin 2 NM_001085376 2.04 0.0198674 0.357 down 43.14 72.29 5.25 6.28
Cobl Cordon-bleu WH2 repeat NM_172496 2.02 0.0168186 0.354 down 9.90 15.74 3.10 4.12
Sparcl1 SPARC-like 1 NM_010097 2.02 0.0128579 0.353 down 176.27 332.24 7.38 8.40
Fbln5 Fibulin 5 NM_011812 2.01 0.0123647 0.353 down 101.10 178.77 6.54 7.54
Table S3:  Predicted target genes common to miR-142-3p, miR-142-5 and/or miR-155.
Related to Figure 5
(From TargetScan, version 7.2 March 2018)
(Genes highlighted in Green are linked to cytokine and/or NFκB signaling)
all 3 miRNAs miR-142-3p/5p miR-142-3p/miR-155
Brwd3 Ap3m1 Acbd3 Acot12 Pura
Hhip Arhgap35 Acvr2a Ankfn1 Qk
Lrp1b Arrdc3 Ago2 Arid2 Rasef
Strn3 Atg16l1 Apc Brd1 Rcn2
Zbtb20 Brwd3 Arntl Brwd3 Reps2
Btbd7 Atxn1l Camta1 Rhoq
Cask Bach1 Cdh12 Rnf146
Ccnt2 Bnc2 Cdon Rps6ka3
Cisd2 Brwd3 Csf1r Rps6ka5
Clcn5 Ehf Cyp7b1 S1pr1
Clock Hhip Dhx40 Sass6
Cpeb2 Lcor Elavl2 Selt
Crk Lrp1b Fam168a Smad2
Fbxo3 Mob4 Fam84a Socs1
Fbxo45 Nfib Fam91a1 Sort1
Fmn1 Picalm Fgf12 Ssh2
Hhip Ppig Fgf13 Strn3
Ipmk Rbm47 Fgf16 Tcf4
Ipo7 Rheb Gsk3b Tle4
Itga8 Rictor H3f3a Tnik
Jmjd1c Rreb1 Hhip Trp53inp1
Lrp1b Slc38a4 Hivep2 Tspan14
Nr3c1 Smug1 Il21 Uba3
Nsd1 Socs6 Irf2bp2 Usp9x
Nucks1 Sox11 Jarid2 Ywhae
Otp Spred1 Kcna4 Zbtb20
Pcgf3 Strn3 Kcnh7 Zdhhc20
Plxnd1 Swt1 Kpna4
Ppp3ca Sypl Kras
Pum1 Tab2 Lrp1b
Rbms1 Thoc1 March7
Rock2 Traf3 Med14
Samd12 Trps1 Meis1
Snx16 Wnk3 Mier3
Stau1 Zbtb20 Myo1d
Strn3 Zfp644 Nfe2l2
Vangl1 Nfia
Zbtb20 Nrp1
Zbtb37 Nsun3
Zcchc14 POU2F1
Zfp827 Prox1
Zfr Ptpn2
miR-142-5p/miR-155
Common target genes
Table S4: Human islet donor information. Related to STAR Methods
Gender Age BMI Purity (%) Viability (%)
Donor #1 Male 53 27.2 80 90
Donor #2 Female 39 31.4 70 90
Donor #3 Female 43 34.0 90 95
Donor #4 Male 50 19.6 80 95
Islets
Table S5: qPCR Primer Sequences. Related to STAR Methods
Forward Reverse
Mouse
18S 5'-GCA ATT ATT CCC CAT GAA CG-3' 5'-GGC CTC ACT AAA CCA TCC AA-3'
Ccl2 5'-AGG TGT CCC AAA GAA GCT GT-3' 5'-ACA GAA GTG CTT GAG GTG GT-3'
Ccl7 5'-ATC TCT GCC ACG CTT CTG T-3' 5'-TAT AGC CTC CTC GAC CCA CT-3'
Cxcl10 5'-GCC GTC ATT TTC TGC CTC AT-3' 5'-GAT AGG CTC GCA GGG ATG AT-3'
Ear12 5'-TCC CGA CTT TGT CTC CTG TT-3' 5'-TTT CCA CAC ACA CCA ACA GC-3'
Gapdh 5’-TGGCAAAGTGGAGATTGTTGCC-3’ 5’-AAGATGGTGATGGGCTTCCCG-3’
Gfp 5’-CTGACCCTGAAGTTCATCTG-3’ 5’- GTCGTCCTTGAAGAAGATGG-3’
H2-Eb2 5'-CTC CTG GTC TGC TCT GTG AT-3' 5'-AAC CAT CTC CAG CAT CAC CA-3'
Hprt 5'-AGTCCCAGCGTCGTGATTAG-3' 5'-AATCCAGCAGGTCAGCAAAG-3'
Ifng 5'-GCT ACA CAC TGC ATC TTG GC-3' 5'-TGT CAC CAT CCT TTT GCC AG-3'
Igfbp2 5'-AAG GTC AAT GAA CAG CAC CG-3' 5'-GCT TGT CAC AGT TGG GGA TG-3'
Pf4 5'-AGC TGT GTG TGT GTG AAG AC-3' 5'-TAT ATA GGG GTG CTT GCC GG-3'
Reg3b 5'-TGG TTT GAT GCA GAA CTG GC-3' 5'-CCA TTC CCA TCC ACC TCC AT-3'
Rat
Ccl2 5'-AGG TGT CCC AAA GAA GCT GT-3' 5'-ACA GAA GTG CTT GAG GTG GT-3'
Ccl7 5'-ATC TCT GCC ACG CTT CTG T-3' 5'-TAT AGC CTC CTC GAC CCA CT-3'
Cxcl10 5'-CCA GTG CTG CTG TCG TTC TC-3' 5'- TCT CAA CAT GCG GAC AGG AT -3'
Hprt 5'-AGTCCCAGCGTCGTGATTAG-3' 5'-AATCCAGCAGGTCAGCAAAG-3'
Human
CCL2 5' - GCA GCA AGT GTC CCA AAG AA-3' 5'- CTG GGG AAA GCT AGG GGA AA-3'
CCL7 5'- CTT CAA CTA CCT GCT GCT ACA-3' 5'-GGG TTT TCT TGT CCA GGT GC-3'
CXCL10 5' -ACT GTA CGC TGT ACC TGC AT-3' 5'- TGA TGG CCT TCG ATT CTG GA-3'
HPRT 5' - CCC TGG CGT CGT GAT TAG TG-3' 5'- GCT ACA ATG TGA TGG CCT CCC-3'
Table S6: miRNA sponge sequence. Related to Figure 7
Mature miRNA sequence
sense anti-sense
miR-142-3p UGUAGUGUUUCCUACUUUAUGGA TCCATAAAGTACTTACACTACA TGTAGTGTAAGTACTTTATGGA
miR-142-5p CAUAAAGUAGAAAGCACUACU AGTAGTGCTAGAACTTTATG CATAAAGTTCTAGCACTACT
miR-150 UCUCCCAACCCUUGUACCAGUG CACTGGTACACCCTTGGGAGA TCTCCCAAGGGTGTACCAGTG
miR-155 UUAAUGCUAAUUGUGAUAGGGGU ACCCCTATCACTAAAGCATTAA TTAATGCTTTAGTGATAGGGGT
Sponge sequence: 
sense:  5’ GTCCC TCCATAAAGTACTTACACTACA CCGG ACCCCTATCACTAAAGCATTAA CCGG AGTAGTGCTAGAACTTTATG CCGG CACTGGTACACCCTTGGGAGA
CCGG TCCATAAAGTACTTACACTACA CCGG ACCCCTATCACTAAAGCATTAA CCGG AGTAGTGCTAGAACTTTATG CCGG CACTGGTACACCCTTGGGAGA GG 3’
anti-sense: 5’ GACCC TCTCCCAAGGGTGTACCAGTG CCGG CATAAAGTTCTAGCACTACT CCGG TTAATGCTTTAGTGATAGGGGT CCGG TGTAGTGTAAGTACTTTATGGA 
CCGG TCTCCCAAGGGTGTACCAGTG CCGG CATAAAGTTCTAGCACTACT CCGG TTAATGCTTTAGTGATAGGGGT CCGG TGTAGTGTAAGTACTTTATGGA GG 3’
Sponge binding sites
